XML 59 R35.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Note 4 - Investment in Wanchun Pharma - Schedule of Equity Method Investment (Details) - USD ($) | Jul. 20, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
--- | --- | --- | --- | ---
Less: net assets of Wanchun Pharma (including cash of $1,256) |  | $ (14,908,000) | $ (10,970,000) |
Wanchun Pharma [Member] |  |  |  |
Acquisition cost | $ 2,400,000 |  |  |
Less: negative equity investment in Wanchun Pharma | (239,000) |  |  | $ (196,000)
Less: net assets of Wanchun Pharma (including cash of $1,256) | (1,347,000) |  |  |
Excess cost allocated to patent of Plinabulin and charged to expenses | $ 814,000 |  |  |

X
- Definition The costs, in excess of equity and assets, of the equity method investment. + References No definition available. + Details
Name: | bysi_ExcessCostOfEquityMethodInvestment
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The liability associated with the holding of certain equity method investments. + References No definition available. + Details
Name: | bysi_InvestmentLiabilityEquityMethodInvestment
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_WanchunPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |